• The ASCO 2021 Podcast

    This podcast surveys state-of-the-art presentations on clinical oncology findings on mCRPC, metastatic oesophageal squamous cell cancer, primary breast cancer, and more.

  • Novel drug combination for recurrent ovarian cancer

    Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial.

  • Circulating tumour DNA to evaluate response in children with neuroblastoma

    In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.

  • Post-nephrectomy pembrolizumab improves disease-free survival

    Adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell RCC.

  • Addition of abiraterone to ADT (plus docetaxel) nearly doubles survival of de novo metastatic prostate cancer

    Adding abiraterone to ADT plus docetaxel significantly improves PFS in patients who present de novo mCSPC without meaningful added short-term toxicity according to phase 3 PEACE-1 trial.

  • Novel dual checkpoint blockade improves progression-free survival in melanoma

    Phase 3 RELATIVITY-047 trial results validate the efficacy of dual checkpoint blockade shown with the LAG-3 inhibitor relatlimab and nivolumab in advanced melanoma patients.

  • Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

    Analysis of phase 3 trials with atezolizumab in stage IV NSCLC patients shows longer overall survival for those experiencing immune-related AEs.

  • Excellent prognosis for breast cancer patients with ultra-low-risk gene signature

    Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.

  • Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

    Patritumab deruxtecan demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced, EGFR-mutated NSCLC.

  • Long-term results from ground-breaking melanoma trials

    After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma.

  • Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

    First-line treatment of patients with MSI-H/dMMR metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for significance was not reached.

  • Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

    The phase 3 OUTBACK trial results do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer.

  • Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

    A significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer is found after 1 year of adjuvant treatment with olaparib.

  • Venetoclax does not benefit ER-positive, HER2-negative metastatic breast cancer

    Adding the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit for ER-positive, HER2-negative, locally advanced/metastatic breast cancer patients.

  • I-O/chemo combo and I-O/I-O combo better than chemotherapy for oesophageal squamous cell cancer

    First phase-3 CheckMate 648 study results demonstrate higher first-line treatment OS with nivolumab + ipilimumab, or nivolumab + chemotherapy, versus chemotherapy only.

  • Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

    A CheckMate 9LA trial update shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced NSCLC.

  • Metastatic castration-resistant prostate cancer: VISION trial meets its endpoints

    Addition of 177Lu-PSMA-617 therapy to standard of care for mCRPC patients significantly improves survival, according to the phase-3 VISION trial results.

  • PARP7 inhibitor shows promising results in first-in-human trial

    RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumour immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial.

  • Molecular tumour profiling: Significant impact on solid tumours in young patients

    First results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling for the diagnosis and treatment of solid tumours in young patients.

  • Breast cancer: Effects on social and professional life underestimated?

    Breast cancer has a greater impact on the quality of life and work of those affected than previously assumed,as found by an ongoing study focused on women with breast cancer during therapy.

  • 1 |
  • 2 |